Drug-induced liver toxicity
DOI:
https://doi.org/10.2478/AMB-2024-0083Keywords:
drug-related disturbances, hepatotoxicity, mechanism, metabolismAbstract
The liver performs many vital functions such as regulating homeostasis, bile production, storage of vitamins, and more. Another important function of the liver is to neutralize toxic substances entering the body. Substances entering the human body can be eliminated unchanged, retained unchanged, or undergo chemical transformation. Drugs are one of the most important and common causes of hepatotoxicity. It can manifest in various forms, ranging from elevated serum levels of transaminases to acute liver failure. The mechanisms of drug-induced liver damage may include the formation of a toxic metabolite (paracetamol), induction of oxidative stress, mitochondrial damage, suppression of key transcription factors and enzymes (methotrexate), suppression of beta-oxidation (valproate), impaired bile secretion and others. In some cases, hepatotoxicity is an idiosyncratic type and the exact mechanism of damage is unclear. Due to the importance of the problem, knowledge about the metabolism, potential adverse drug reactions, and the correct dosage regimen is essential.
References
Bhakuni GS, Bedi O, Bariwal J, et al. Animal models of hepatotoxicity. Inflamm Res, 2016, 65(1):13–24. https://doi. org/10.1007/s00011-015-0883-0
Andrade RJ, Robles M, Fernández-Castañer A, et al. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol, 2017, 13(3):329-340. https://doi.org/10.3748/wjg.v13.i3.329
Thompson WL, Takebe T. Human liver model systems in a dish. Dev Growth Differ, 2021, 63(1):47–58. https://doi. org/10.1111/dgd.12708
Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology, 2006, 43(1):54–62. https://doi.org/10.1002/ hep.21060
MacParland SA, Liu JC, Ma XZ, et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macro
phage populations. Nat Commun, 2018, 9(1):4383. https:// doi.org/10.1038/s41467-018-06318-7
Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol, 2017, 27(21):1147–1151. https://doi.org/10.1016/j.cub.2017.09.019
Simeonova R, Vitcheva V, Kondeva-Burdina M, et al. Hepatoprotective and antioxidant effects of saponarin, isolated from Gypsophila trichotoma Wend. on paracetamol-induced liver damage in rats. BioMed Res Int, 2013, 2013:757126. https:// doi.org/10.1155/2013/757126
Croom E. Metabolism of xenobiotics of human environments. Prog Mol Biol Transl Sci, 2012, 112:31-88. https://doi. org/10.1016/B978-0-12-415813-9.00003-9
Naik A, Belič A, Zanger UM, et al. Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet, 2013, 4:2. https://doi.org/10.3389/fgene.2013.00002
Hodgson E, Rose RL. Metabolism of toxicants. In: A Textbook of Modern Toxicology. 4th ed. E. Hodgson (Ed.). New Jersey, John Wiley & Sons, Inc., Hoboken, 2010, 115–155.
Omiecinski CJ, Vanden Heuvel JP, Perdew GH, et al. Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci, 2011, 120(1):49-75. https://doi.org/10.1093/ toxsci/kfq338
LeBlanc GA. Phase II—conjugation of toxicants. In: Molecular and biochemical toxicology. 4th ed. R. C. Smart, E. Hodgson (Eds.). New Jersey, John Wiley & Sons, Inc., Hoboken, 2008, 219–237.
Tittarelli R, Pellegrini M, Scarpellini MG, et al. Hepatotoxicity of paracetamol and related fatalities. Eur Rev Med Pharmacol Sci, 2017, 21(1):95-101. https://www.europeanreview.org/wp/ wp-content/uploads/95-101-Hepatotoxicity-of-paracetamol-and-related-fatalities.pdf
Leung L. From ladder to platform: a new concept for pain management. J Prim Health Care, 2012, 4:254-258. DOI:10.1071/ HC12258
Massart J, Begriche K, Fromenty B. Cytochrome P450 2E1 should not be neglected for acetaminophen-induced liver injury in metabolic diseases with altered insulin levels or glucose homeostasis. Clin Res Hepatol Gastroenterol, 2021, 45(1):101470. https://doi.org/10.1016/j.clinre.2020.05.018
Lancaster EM, Hiatt JR, Zarrinpar A. Acetaminophen hepatotoxicity: an update review. Arch Toxicol, 2015, 89:193-199. https://doi.org/10.1007/s00204-014-1432-2
Begriche K, Penhoat C, Bernabeu-Gentey P, et al. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 2023, 3(1):33-53. https://doi.org/10.3390/livers3010003
McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res, 2013, 30:2174-2187. https://doi. org/10.1007/s11095-013-1007-6
Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol, 2016, 28:131-142. https://doi.org/10.14218/ JCTH.2015.00052
Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev, 2012, 44:88-106. https://doi.org/10.3109/03 602532.2011.602688
Meunier L, Larrey D. Recent advances in hepatotoxicity of non steroidal anti-inflammatory drugs. Annals of Hepatology, 2018,
(2):187–191. https://doi.org/10.5604/01.3001.0010.8633
Simmons DL, Botting RM, Hla T. Ciclooxigenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev, 2004, 56(3):387-437. https://doi.org/10.1124/ pr.56.3.3
Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Current medicinal chemistry, 2000, 7:11131120. https://doi.org/10.2174/0929867003374282
Bacchi S, Palumbo P, Sponta A, et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem, 2012, 11(1):52–64. https://doi.org/10.2174/187152312803476255
Lewis JH, Stine JG. Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists. In: Drug-induced liver disease. 3rd ed. N. Kaplowitz, D. L. DeLeve (Eds.). Paris, Elsevier, 2013, 369-401.
O’Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM, 2003, 96(11):787–791. https://doi.org/10.1093/qjmed/hcg138
Zoubek ME, Lucena MI, Andrade RJ, et al. Systematic review: ibuprofen-induced liver injury. Aliment Pharmacol Ther, 2020, 51(6):603-611. https://doi.org/10.1111/apt.15645
Schmeltzer PA, Kosinski AS, Kleiner DE, et al. Liver injury from nonsteroi dal anti-inflammatory drugs in the United States. Liver Int, 2016, 36:603-609. https://doi.org/10.1111/ liv.13032
Nouri A, Heidarian E, Nikoukar M. Effects of N-acetyl cysteine on oxidative stress and TNF-α gene expression in diclofenac-induced hepatotoxicity in rats. Toxicol Mech Methods, 2017, 27(8):561–567. https://doi.org/10.1080/15376516.2017.1334732
Kalra V. Reyes Syndrome. Apollo Medicine, 2008, 5(2):106-110. https://doi.org/10.1016/S0976-0016(11)60130-0
Sahu CR. Mechanisms involved in toxicity of liver caused by piroxicam in mice and protective effects of leaf extract of Hibiscus rosa-sinensis L. Clin Med Insights Arthritis Musculoskelet Disord, 2016, 9:9-13. https://doi.org/10.4137/CMAMD. S29463
Badawi MS. Histological study of the protective role of ginger on piroxicam-induced liver toxicity in mice. J Chin Med Assoc, 2019, 82(1):11-18. https://doi.org/10.1016/j.jcma.2018.06.006
Rainsford K. Anti-inflammatory drugs in the 21st century. Sub-cellular biochemistry, 2007, 42:3–27. https://doi.org/10.1007/1-4020-5688-5_1
Famularo G, Gasbarrone L, Minisola G. Probable celecoxibinduced hepatorenal syndrome. Ann Pharmacother, 2012, 46:610–611. https://doi.org/10.1345/aph.1Q671
Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf, 2010, 19:708–714. https://doi.org/10.1002/pds.1966
Pugh AJ, Barve AJ, Falkner K, et al. Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis, 2009, 13(2):277-294. https://doi.org/10.1016/j.cld.2009.02.008
Appiah J, Prasad A, Shah V, et al. Amoxicillin-clavulanate induced liver injury in a young female. Cureus, 2023, 15(1):e33445. https://doi.org/10.7759/cureus.33445
Polson JE. Hepatotoxicity due to antibiotics. Clin Liver Dis, 2007, 11(3):549-561. https://doi.org/10.1016/j. cld.2007.06.009
O’Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II associations. Gut, 2000, 47:717–720. https://doi.org/10.1136/ gut.47.5.717
Fox JC, Szyjkowski RS, Sanderson SO, et al. Progressive cholestatic liver disease associated with clarithromycin treatment. The Journal of Clinical Pharmacology, 2002, 42(6):676-680. https://doi.org/10.1177/00970002042006011
Westphal JF, Brogard JM. Antibacterials and antifungal agents. In: Drug-induced liver disease. N. Kaplowitz, L. D. DeLeve (Eds.). New York, Marcel-Dekker, 2003, 471–504.
Robles M, Toscano E, Cotta J, et al. Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. Curr Drug Saf, 2010, 5(3):212-222. https://doi. org/10.2174/157488610791698307
Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs,
, 16(10):669-694. https://doi.org/10.2165/00023210-200216100-00003
Smits JE, Wallenburg E, van Spanje A, et al. Valproate intoxication in a patient with blood valproate levels within therapeutic range. J Clin Psychiatry, 2017, 78(4):413-414. https://doi. org/10.4088/JCP.15cr10147
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
Patel AR, Nagalli S. Valproate Toxicity. Treasure Island (FL): StatPearls [Updated 2021 Nov 25; cited 2022 March 4]. Available from: https://www.statpearls.com/ArticleLibrary/viewarticle/30391
Mahmoud AM, Hussein OE, Hozayen WG, et al. Methotrexate hepatotoxicity is associated with oxidative stress, and down-regulation of PPARγ and Nrf2: Protective effect of 18β-Glycyrrhetinic acid. Chem Biol Interact, 2017, 270:59-72. https://doi.org/10.1016/j.cbi.2017.04.009
Abo-Haded HM, Elkablawy MA, Al-Johani Z, et al. Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. PLoS One, 2017, 12(3):e0174295. https://doi. org/10.1371/journal.pone.0174295
Ezhilarasan D. Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms. Toxicology, 2021, 458:152840. https://doi.org/10.1016/j. tox.2021.152840
Santhakumar P, Roy A, Ganesh MK, et al. Ethanolic extract of Capparis decidua fruit ameliorates methotrexate-induced hepatotoxicity by suppressing oxidative stress and inflammation by modulating nuclear factor-kappa B signaling pathway. Pharmacogn Mag, 2021, 17:143-150. DOI:10.4103/ pm.pm_402_20
Combrink M, du Preez I. Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. Toxicology letters, 2020, 322:104-110. https://doi.org/10.1016/j. toxlet.2020.01.018
Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazidinduced hepatotoxicity: then and now. Br J Clin Pharmacol, 2016, 81(6):1030-1036. doi:10.1111/bcp.12885
Jia ZL, Cen J, Wang JB, et al. Mechanism of isoniazidinduced hepatotoxicity in zebrafish larvae: activation of ROS-mediated ERS, apoptosis and the Nrf2 pathway. Chemosphere, 2019, 227:541-550. https://doi.org/10.1016/j.chemosphere.2019.04.026
Lei S, Gu R, Ma X. Clinical perspectives of isoniazid-induced liver injury. Liver Research, 2021, 5:45-52. https://doi. org/10.1016/j.livres.2021.02.001
Yang S, Hwang SJ, Park JY, et al. Association of genetic polymorphisms of CYP2E1, NAT2, GST, and SLCO1B1, with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ Open, 2019, 9(8):e027940. https://doi.org/10.1136/bmjopen-2018-027940
Santoso SB, Pribadi P, Irham LM. Isoniazid-induced liver injury risk level in different variants of N-acetyltransferase 2 (NAT2) polymorphisms: a literature review. Pharmacia, 2023, 70(4):973-981. https://doi.org/10.3897/pharmacia.70. e109869
Downloads
Published
Issue
Section
License
Copyright (c) 2024 K. Stavrakeva, M. Popova, M. Esad, E. Apostolva, V. Kokova, M. Bacelova, A. Alakidi, A. Bivolarska (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
